← Back to Clinical Trials
Recruiting NCT06494423

NCT06494423 Employment Support After Hematopoietic Stem Cell Transplantation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06494423
Status Recruiting
Phase
Sponsor MGH Institute of Health Professions
Condition Hematopoietic Stem Cell Transplantation
Study Type INTERVENTIONAL
Enrollment 35 participants
Start Date 2024-07-31
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Work Support (WorkS)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 35 participants in total. It began in 2024-07-31 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a feasibility study of a Work Support (WorkS) intervention designed to ameliorate employment challenges for people preparing to return to work after allogeneic stem cell transplantation. The aim of this study is to evaluate "proof of concept" by: 1. examining the feasibility and acceptability of the WorkS intervention and the study procedures, and 2. exploring the preliminary effects of WorkS for improving patient-reported return-to-work self-efficacy, work status, quality of life, and financial toxicity.

Eligibility Criteria

Inclusion Criteria: * Received an allogeneic HSCT within the past six months to treat a hematological malignancy. * Screen positive for work-related concerns (i.e., responds "yes" to the question, "Are you concerned about your ability to return to work in the coming six months?") Exclusion Criteria: * Patients with acute psychiatric or cognitive conditions which the treating clinician believes prohibits informed consent or compliance with the study procedures * We will not enroll the following special populations: adults unable to consent, individuals not yet adults, pregnant women, and prisoners.

Contact & Investigator

Central Contact

Kathleen Lyons, ScD, OTR/L

✉ klyons2@mghihp.edu

📞 614-643-5372

Principal Investigator

Kathleen Lyons, ScD, OTR/L

PRINCIPAL INVESTIGATOR

MGH Institute of Health Professions

Frequently Asked Questions

Who can join the NCT06494423 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Hematopoietic Stem Cell Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06494423 currently recruiting?

Yes, NCT06494423 is actively recruiting participants. Contact the research team at klyons2@mghihp.edu for enrollment information.

Where is the NCT06494423 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT06494423 clinical trial?

NCT06494423 is sponsored by MGH Institute of Health Professions. The principal investigator is Kathleen Lyons, ScD, OTR/L at MGH Institute of Health Professions. The trial plans to enroll 35 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology